Open menu Close menu Open Search Close search

Thrombin-JMI (King)

  • Description
  • Clinical Pharmacology
  • Indications and Usage
  • Contraindications
  • Warnings
  • Precautions
  • Adverse Reactions
  • Dosage and Administration
  • How Supplied

    - Drugs index
    - Manufacturers
    - Feedback

  • Thrombin, Topical (Bovine) must not be injected! Apply on the surface of bleeding tissue.


    The thrombin in Thrombin, Topical (Bovine Origin) THROMBIN-JMI® is a protein substance produced through a conversion reaction in which prothrombin of bovine origin is activated by tissue thromboplastin of bovine origin in the presence of calcium chloride. It is supplied as a sterile powder that has been freeze-dried in the final container. Also contained in the preparation are mannitol and sodium chloride. Mannitol is included to make the dried product fri-able and more readily soluble. The material contains no preservative.

    THROMBIN-JMI® has been chromatographically purified.


    THROMBIN-JMI® requires no intermediate physiological agent for its action. It clots the fibrinogen of the blood directly. Failure to clot blood occurs in the rare case where the primary clotting defect is the absence of fibrinogen itself. The speed with which thrombin clots blood is dependent upon the concentration of both thrombin and fibrinogen.


    THROMBIN-JMI® is indicated as an aid to hemostasis whenever oozing blood and minor bleeding from capillaries and small venules is accessible.

    In various types of surgery, solutions of THROMBIN-JMI® may be used in conjunction with an Absorbable Gelatin Sponge, USP for hemostasis.


    THROMBIN-JMI® is contraindicated in persons known to be sensitive to any of its components and/or to material of bovine origin.


    The use of topical bovine thrombin preparations has occasionally been associated with abnormalities in hemostasis ranging from asymptomatic alterations in laboratory determinations, such as prothrombin time (PT) and partial thromboplastin time (PTT), to severe bleeding or thrombosis which rarely have been fatal. These hemostatic effects appear to be related to the formation of antibodies against bovine thrombin and/or factor V which in some cases may cross react with human factor V, potentially resulting in factor V deficency. Repeated clinical applications of topical bovine thrombin increase the likelihood that antibodies against thrombin and/or factor V may be formed. Consultation with an expert in coagulation disorders is recommended if a patient exhibits abnormal coagulation laboratory values, abnormal bleeding, or abnormal thrombosis following the use of topical thrombin. Any interventions should consider the immunologic basis of this condition. Patients with antibodies to bovine thrombin preparations should not be re-exposed to these products.

    Because of its action in the clotting mechanism, THROMBIN-JMI® must not be injected or otherwise allowed to enter large blood vessels. Extensive intravascular clotting and even death may result.


    General --Consult the Absorbable Gelatin Sponge, USP labeling for complete information for use prior to utilizing the thrombin saturated sponge procedure.

    Pregnancy--Category C - Animal reproduction studies have not been conducted with THROMBIN-JMI®. It is also not known whether THROMBIN-JMI® can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. THROMBIN-JMI® should be given to a pregnant woman only if clearly indicated.

    Pediatric Use --Safety and effectiveness in children have not been established.


    Allergic reactions may be encountered in persons known to be sensitive to bovine materials. Inhibitory antibodies which interfere with hemostasis may develop in a small percentage of patients. See Warning .


    Solutions of Thrombin, Topical (Bovine Origin), USP, THROMBIN-JMI® may be reconstituted with sterile isotonic saline at a recommended concentration of 1,000 to 2,000 International Units/mL. Where bleeding is profuse, as from abraded surfaces of liver or spleen, concentrations of 1,000 International Units per mL may be required. For general use in plastic surgery, dental extractions, skin grafting, etc. solutions containing approximately 100 International Units/mL are frequently used. Intermediate strengths to suit the needs of the case may be prepared by diluting the contents of the THROMBIN-JMI® container with an appropriate volume of sterile isotonic saline. In many situations, it may be advantageous to use THROMBIN-JMI® in a dry form on oozing surfaces. THROMBIN-JMI® may also be used with FloSeal™ NT according to the directions for use in the FloSeal™ NT package insert.

    In instances where a concentration of approximately 1,000 units/mL is desired, the contents of the vial of ster-ile isotonic saline diluent may be transferred into the THROMBIN-JMI® container with a sterile syringe or sterile transfer needle. If the transfer needle is used for reconstitution, transfer the diluent in the following manner.

    1. Remove the plastic cap off of the diluent vial.
    2. Twist the clear plastic cover on the transfer needle and remove.
    3. Insert the exposed needle into the diaphragm of the diluent vial.
    4. Flip the plastic cover up on the THROMBIN-JMI® container. DO NOT REMOVE THE ALUMINUM SEAL.
    5. Remove the pink plastic cap from the transfer needle exposing the needle.
    6. Invert the vial of diluent and insert the exposed needle into the diaphragm of the THROMBIN-JMI® container.


    Each spray kit contains one vial of THROMBIN-JMI®, one vial of diluent and one spray pump and actuator.

    1. Remove the outer lid by pulling up at the indicated edge. The inner tray is sterile and suitable for introduction into any operating field.
    2. Remove the cover on inner tray to expose sterile contents.
    3. Reconstitute the THROMBIN-JMI® to desired potency by introducing sterile isotonic saline with a sterile syringe or a sterile transfer needle. If the transfer needle is used, follow the previously described procedure.
    4. When the THROMBIN-JMI® is completely dissolved, open vial by flipping up metal and tearing counterclockwise.
    5. Remove the rubber diaphragm from vial. Remove pump with protective cap from tray and snap onto vial. Remove protective cap and attach actuator.
    6. To spray, hold vial upright or at a slight angle. Several strokes of the pump will be required to expel the solution.
    7. Discard unused contents and pump: DO NOT TRANSFER SPRAY PUMP TO ANOTHER VIAL.


    Each syringe kit contains one vial of THROMBIN-JMI®, one vial of diluent and one spray tip and syringe.

    1. Remove the outer lid by pulling up at the indicated edge. The inner tray is sterile and suitable for introduction into any operating field.
    2. Remove the cover on the inner tray to expose sterile contents.
    3. Using the sterile syringe equipped with a needle, draw the desired amount of saline diluent from the vial into the syringe.
    4. Inject the saline diluent into the THROMBIN-JMI® thrombin vial from the syringe to reconstitute the THROMBIN-JMI® thrombin powder.
    5. When the THROMBIN-JMI® powder is completely dissolved, draw the THROMBIN-JMI® Thrombin solution into the syringe.
    6. Replace the needle guard.
    7. Turn needle guard counterclockwise and remove and discard the needle.
    8. Affix spray tip by pushing down and turning clockwise until the spray tip locks in place.
    9. To spray, depress the syringe plunger in a normal fashion to dispense the THROMBIN-JMI® Thrombin solution through the tip in a fine spray.
    10. Discard unused contents and syringe.

    CAUTION: Solutions should be used promptly upon removal from the container. However, the solution may be refrigerated at 2-8°C for up to three hours.

    The following techniques are suggested for the topical application of THROMBIN-JMI®.

    1. The recipient surface should be sponged (not wiped) free of blood before THROMBIN-JMI® is applied.
    2. A spray may be used or the surface may be flooded using a sterile syringe and small gauge needle. The most effective hemostasis results occur when the THROMBIN-JMI® mixes freely with the blood as soon as it reaches the surface.
    3. Sponging of the treated surfaces should be avoided to assure that the clot remains securely in place.

    THROMBIN-JMI® may be used in conjunction with Absorbable Gelatin Sponge, USP as follows:

    1. Prepare THROMBIN-JMI® solution to desired strength.
    2. Immerse sponge strips of the desired size in THROMBIN-JMI® solution. Knead the sponge strips vigorously with moistened, gloved fingers to remove trapped air, thereby facilitating saturation of the sponge.
    3. Apply saturated sponge to bleeding area. Hold in place with a pledget of cotton or a small gauze sponge until hemostasis occurs.


    THROMBIN-JMI® is supplied in the following packages:

    NDC 052604-7102-1...5,000 International Unit vial with 5 mL diluent.

    NDC 052604-7105-320,000 International Unit vial with 20 mL diluent.

    THROMBIN-JMI® Spray Kit is supplied in the following packages:

    NDC 052604-7105-220,000 International Unit vial with 20 mL diluent, spray pump and actuator.

    THROMBIN-JMI® Syringe Spray Kit is supplied in the following packages:

    NDC 052604-7355-220,000 International Unit vial with 20 mL diluent, spray tip and syringe.


    Store THROMBIN-JMI® at 2°-25°C (36°-77°F).

    Prescribing Information as of May 2005.

    Distributed By:

    Jones Pharma Incorporated

    Bristol, VA 24201

    Manufactured by:

    GenTrac, Incorporated

    Middleton, Wisconsin 53562

    U.S. License No. 977

    - To bookmark this page (add it to your favorites), please click the image to the left.
    - If you wish to link to this page, you can do so by referring to the URL address below this line.

    This page was last modified 30-JUN-07
    Copyright © 1995-2021 ITA all rights reserved.